|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-1-27
|
|
pubmed:abstractText |
Structurally altered proteins (derived from chromosomal translocations or gene mutations) can be considered tumor specific antigens and represent an attractive target for a T-cell mediated response. T lymphocytes recognize antigens in the form of peptides bound to HLA-molecules.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0300-8916
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
83
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
847-55
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9428921-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:9428921-Fluorescent Antibody Technique, Indirect,
pubmed-meshheading:9428921-Genes, MHC Class I,
pubmed-meshheading:9428921-HLA Antigens,
pubmed-meshheading:9428921-Humans,
pubmed-meshheading:9428921-Mutation,
pubmed-meshheading:9428921-Oncogene Proteins, Fusion,
pubmed-meshheading:9428921-Proto-Oncogene Protein c-fli-1,
pubmed-meshheading:9428921-RNA-Binding Protein EWS,
pubmed-meshheading:9428921-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:9428921-Thymidine,
pubmed-meshheading:9428921-Transcription Factors,
pubmed-meshheading:9428921-ras Proteins
|
|
pubmed:articleTitle |
HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins.
|
|
pubmed:affiliation |
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
